Xarelto

M Levin, MD — Thu, 29 Nov 2012 14:42:55 +0000

Xarelto is the first oral blood thinner approved for anti-coagulation in 60 years, since Warfarin (coumadin) was approved. A variety of injectable options are available; however, the oral route is preferred by many physicians and patients. Xarelto joins the much older Coumadin as an oral medication. Previouwly Xarelto was only approved for Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation. In November 2012, the U.S. Food and Drug Administration expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment. .

The approval was approved based on three clinical studies that showed it to be as effective as the enoxaparin and coumadin for treating DVT and PE. With these results, when oral preparations are preferred for tratment of DVT or PE, Xarelto appears to have an advantage over injectable anticoagulants.

For Professional version see here

Home treatment of DVT

M Levin, MD — Wed, 20 Jun 2012 18:25:21 +0000

Deep Venous Thrombosis is a common problem and its treatment usually starts with a hospitalization for IV heparin. Home treatment of newly diagnoses DVT would be a boon to patients and reduce costs of the overburdened health care system. Four criteria can be used to identify patients with DVT for whom outpatient treatment might not be appropriate: presence of massive DVT, presence of symptomatic pulmonary embolism, high risk of bleeding with anticoagulant therapy, and presence of other conditions or other factors that warrant in-hospital care. This is an extensively studied subject and at this point, limited literature evidence suggests that home management is cost effective and preferred by patients.

Read the Professional version here.

Cancer Treatment Today » DVT

Xarelto

Home treatment of DVT